Optison imaging agent sales begin to take off
This article was originally published in Clinica
Executive Summary
Clinical acceptance of Optison, the only FDA-approved gas-filled albumin bubble ultrasound contrast imaging agent, is beginning to grow, according to Molecular Biosystems, with end-user sales growing 25%, comparing the first quarter of 1999 with the last quarter of 1998. However, the San Diego, California-based company conceded that the increased end-user sales of the myocardial perfusion contrast imaging agent came from stock already purchased by its marketing partner, Mallinckrodt.